TY - JOUR
T1 - Engaging European society at the forefront of cancer research and care
T2 - How discussions at the 5th Gago Conference on European Science policy led to the Heidelberg Manifesto
AU - Baumann, Michael
AU - Celis, Julio
AU - Ringborg, Ulrik
AU - Heitor, Manuel
AU - Berns, Anton
AU - Albreht, Tit
AU - Arabadjiev, Jeliazko
AU - Boutros, Michael
AU - Brandenburg, Mario
AU - Canhao, Helena
AU - Carneiro, Fatima
AU - Chomienne, Christine
AU - De Lorenzo, Francesco
AU - Eggermont, Alexander M.M.
AU - Font, Angel
AU - Garralda, Elena
AU - Goulart, Margarida
AU - Henrique, Rui
AU - Lawler, Mark
AU - Maier-Hein, Lena
AU - Meunier, Francoise
AU - Oberst, Simon
AU - Oliveira, Pedro
AU - Papatriantafyllou, Maria
AU - Schüz, Joachim
AU - Solary, Eric
AU - Valencia, Alfonso
AU - Vargas, Rosalia
AU - Weiderpass, Elisabete
AU - Wilking, Nils
N1 - Funding Information:
Finally, Dr Garralda highlighted progress made by Cancer Core Europe (CCE), an independent consortium of major cancer centres in Europe that have worked together to create a multi‐site European Cancer Institute, where joint translation and clinical research is performed, with a special focus on next‐generation clinical trials and precision medicine. The creation of large, shared databases through CCE is expected to accelerate cancer diagnosis, clinical decisions, and outcomes research throughout Europe, even when small subsets of cancer patients are targeted. The Basket of Baskets (BoB) multimodal clinical trial design and the CCE Molecular Tumour Board exemplify how the above can be achieved [ 22,23 ] and have further developed with the recent funding from the EU's Horizon 2020 research and innovation programme to build data‐rich clinical trials (DART). The DART project was launched in February 2021, with the aim to develop digital tools for trial management and clinical decision‐making. DART is expected to improve clinical trial methodology through the introduction of new statistical designs. Moreover, it aims at integrating more accurate imaging and molecular biomarkers of treatment responses into a new generation of clinical trials, while also ensuring patient empowerment and involvement or engagement (Table 2 ).
Funding Information:
Research discussed by Elena Garralda has been funded by CaixaResearch Advanced Oncology Research Program supported by Fundació La Caixa (LCF/PR/CE07/50610001) and by the European Union under grant agreements no. 965397 (CC‐DART) and 101079984 (PCM4EU). Authors are grateful to Christina von Gertten for preparation of the manuscript.
Publisher Copyright:
© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
PY - 2023/6
Y1 - 2023/6
N2 - European cancer research stakeholders met in October 2022 in Heidelberg, Germany, at the 5th Gago conference on European Cancer Policy, to discuss the current cancer research and cancer care policy landscape in Europe. Meeting participants highlighted gaps in the existing European programmes focusing on cancer research, including Europe's Beating Cancer Plan (EBCP), the Mission on Cancer (MoC), Understanding Cancer (UNCAN.eu), and the joint action CRANE, and put forward the next priorities, in the form of the Heidelberg Manifesto for cancer research. This meeting report presents all discussions that shed light on how infrastructures can be effectively shaped for translational, prevention, clinical and outcomes cancer research, with a focus on implementation and sustainability and while engaging patients and the public. In addition, we summarize recommendations on how to introduce frameworks for the digitalization of European cancer research. Finally, we discuss what structures, commitment, and resources are needed to establish a collaborative cancer research environment in Europe to achieve the scale required for innovation.
AB - European cancer research stakeholders met in October 2022 in Heidelberg, Germany, at the 5th Gago conference on European Cancer Policy, to discuss the current cancer research and cancer care policy landscape in Europe. Meeting participants highlighted gaps in the existing European programmes focusing on cancer research, including Europe's Beating Cancer Plan (EBCP), the Mission on Cancer (MoC), Understanding Cancer (UNCAN.eu), and the joint action CRANE, and put forward the next priorities, in the form of the Heidelberg Manifesto for cancer research. This meeting report presents all discussions that shed light on how infrastructures can be effectively shaped for translational, prevention, clinical and outcomes cancer research, with a focus on implementation and sustainability and while engaging patients and the public. In addition, we summarize recommendations on how to introduce frameworks for the digitalization of European cancer research. Finally, we discuss what structures, commitment, and resources are needed to establish a collaborative cancer research environment in Europe to achieve the scale required for innovation.
KW - cancer prevention
KW - cancer research
KW - Mission on Cancer
KW - policy
UR - http://www.scopus.com/inward/record.url?scp=85158097291&partnerID=8YFLogxK
U2 - 10.1002/1878-0261.13423
DO - 10.1002/1878-0261.13423
M3 - Article
C2 - 36938773
AN - SCOPUS:85158097291
SN - 1574-7891
VL - 17
SP - 925
EP - 945
JO - Molecular Oncology
JF - Molecular Oncology
IS - 6
ER -
